These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 12481190

  • 1. YM872: a selective, potent and highly water-soluble alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist.
    Takahashi M, Kohara A, Shishikura J, Kawasaki-Yatsugi S, Ni JW, Yatsugi S, Sakamoto S, Okada M, Shimizu-Sasamata M, Yamaguchi T.
    CNS Drug Rev; 2002; 8(4):337-52. PubMed ID: 12481190
    [Abstract] [Full Text] [Related]

  • 2. Neuroprotective efficacy of YM872, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, after permanent middle cerebral artery occlusion in rats.
    Takahashi M, Ni JW, Kawasaki-Yatsugi S, Toya T, Ichiki C, Yatsugi SI, Koshiya K, Shimizu-Sasamata M, Yamaguchi T.
    J Pharmacol Exp Ther; 1998 Nov; 287(2):559-66. PubMed ID: 9808681
    [Abstract] [Full Text] [Related]

  • 3. YM872, a novel selective alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, reduces brain damage after permanent focal cerebral ischemia in cats.
    Takahashi M, Ni JW, Kawasaki-Yatsugi S, Toya T, Yatsugi SI, Shimizu-Sasamata M, Koshiya K, Shishikura JI, Sakamoto S, Yamaguchi T.
    J Pharmacol Exp Ther; 1998 Feb; 284(2):467-73. PubMed ID: 9454786
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A novel AMPA receptor antagonist, YM872, reduces infarct size after middle cerebral artery occlusion in rats.
    Kawasaki-Yatsugi S, Yatsugi S, Takahashi M, Toya T, Ichiki C, Shimizu-Sasamata M, Yamaguchi T, Minematsu K.
    Brain Res; 1998 May 18; 793(1-2):39-46. PubMed ID: 9630503
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. YM872, a highly water-soluble AMPA receptor antagonist, preserves the hemodynamic penumbra and reduces brain injury after permanent focal ischemia in rats.
    Shimizu-Sasamata M, Kano T, Rogowska J, Wolf GL, Moskowitz MA, Lo EH.
    Stroke; 1998 Oct 18; 29(10):2141-8. PubMed ID: 9756596
    [Abstract] [Full Text] [Related]

  • 9. The spinal antinociceptive effects of a novel competitive AMPA receptor antagonist, YM872, on thermal or formalin-induced pain in rats.
    Nishiyama T, Gyermek L, Lee C, Kawasaki-Yatsugi S, Yamaguchi T.
    Anesth Analg; 1999 Jul 18; 89(1):143-7. PubMed ID: 10389792
    [Abstract] [Full Text] [Related]

  • 10. YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist.
    Shimizu-Sasamata M, Kawasaki-Yatsugi S, Okada M, Sakamoto S, Yatsugi S, Togami J, Hatanaka K, Ohmori J, Koshiya K, Usuda S, Murase K.
    J Pharmacol Exp Ther; 1996 Jan 18; 276(1):84-92. PubMed ID: 8558460
    [Abstract] [Full Text] [Related]

  • 11. Neuroprotective effect of the novel glutamate AMPA receptor antagonist YM872 assessed with in vivo MR imaging of rat MCA occlusion.
    Håberg A, Takahashi M, Yamaguchi T, Hjelstuen M, Haraldseth O.
    Brain Res; 1998 Nov 16; 811(1-2):63-70. PubMed ID: 9804894
    [Abstract] [Full Text] [Related]

  • 12. The systemically administered competitive AMPA receptor antagonist, YM872, has analgesic effects on thermal or formalin-induced pain in rats.
    Nishiyama T, Gyermek L, Lee C, Kawasaki-Yatsugi S, Yamaguchi T.
    Anesth Analg; 1999 Dec 16; 89(6):1534-7. PubMed ID: 10589643
    [Abstract] [Full Text] [Related]

  • 13. AMPA receptor antagonist, YM90K, reduces infarct volume in thrombotic distal middle cerebral artery occlusion in spontaneously hypertensive rats.
    Yao H, Ibayashi S, Nakane H, Cai H, Uchimura H, Fujishima M.
    Brain Res; 1997 Apr 04; 753(1):80-5. PubMed ID: 9125434
    [Abstract] [Full Text] [Related]

  • 14. Effect of YM872, a selective and highly water-soluble AMPA receptor antagonist, in the rat kindling and rekindling model of epilepsy.
    Hara H, Yamada N, Kodama M, Matsumoto Y, Wake Y, Kuroda S.
    Eur J Pharmacol; 2006 Feb 15; 531(1-3):59-65. PubMed ID: 16403498
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Neuroprotective effect of a novel AMPA receptor antagonist, YM90K, in rat focal cerebral ischaemia.
    Umemura K, Shimakura A, Nakashima M.
    Brain Res; 1997 Oct 31; 773(1-2):61-5. PubMed ID: 9409705
    [Abstract] [Full Text] [Related]

  • 18. Effect of AMPA receptor antagonist YM872 on cerebral hematoma size and neurological recovery in the intracerebral hemorrhage rat model.
    Terai K, Suzuki M, Sasamata M, Yatsugi Si, Yamaguchi T, Miyata K.
    Eur J Pharmacol; 2003 Apr 25; 467(1-3):95-101. PubMed ID: 12706461
    [Abstract] [Full Text] [Related]

  • 19. Delayed treatment with YM90K, an AMPA receptor antagonist, protects against ischaemic damage after middle cerebral artery occlusion in rats.
    Kawasaki-Yatsugi S, Shimizu-Sasamata M, Yatsugi S, Yamaguchi T.
    J Pharm Pharmacol; 1998 Aug 25; 50(8):891-8. PubMed ID: 9751454
    [Abstract] [Full Text] [Related]

  • 20. Effects of YM872 on atrophy of substantia nigra reticulata after focal ischemia in rats.
    Ni JW, Takahashi M, Yatsugi S, Shimizu-Sasamata M, Yamaguchi T.
    Neuroreport; 1998 Nov 16; 9(16):3719-24. PubMed ID: 9858385
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.